Genetic Technologies Ltd ADR GENE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GENE is a good fit for your portfolio.
News
-
Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial
-
GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment
-
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
-
GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network
-
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV
-
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
-
GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner
Trading Information
- Previous Close Price
- $0.73
- Day Range
- $0.63–0.73
- 52-Week Range
- $0.63–1.90
- Bid/Ask
- $0.70 / $0.70
- Market Cap
- $13.18 Mil
- Volume/Avg
- 231,968 / 114,301
Key Statistics
- Price/Earnings (Normalized)
- 115.81
- Price/Sales
- 9.91
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 60
- Website
- https://www.gtglabs.com
Valuation
|
Metric
|
GENE
|
|---|---|
Price/Earnings (Normalized) | 115.81 |
Price/Book Value | 8.92 |
Price/Sales | 9.91 |
Price/Cash Flow | — |
Price/Earnings
GENE
Financial Strength
|
Metric
|
GENE
|
|---|---|
Quick Ratio | 2.95 |
Current Ratio | 3.17 |
Interest Coverage | — |
Quick Ratio
GENE
Profitability
|
Metric
|
GENE
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GENE
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Xlmj | $191.7 Bil | |
DHR
| Danaher Corp | Lbnttn | $165.1 Bil | |
IDXX
| IDEXX Laboratories Inc | Sckjvn | $40.1 Bil | |
IQV
| IQVIA Holdings Inc | Brfkqb | $39.6 Bil | |
A
| Agilent Technologies Inc | Kxqrv | $37.6 Bil | |
MTD
| Mettler-Toledo International Inc | Cjsvgz | $23.9 Bil | |
ICLR
| Icon PLC | Fjhxl | $22.2 Bil | |
LH
| Laboratory Corp of America Holdings | Hqxgrpb | $18.6 Bil | |
ILMN
| Illumina Inc | Qtzdsp | $17.4 Bil | |
WAT
| Waters Corp | Fnpk | $17.1 Bil |